Vontobel Holding Ltd. Sells 3,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)

Vontobel Holding Ltd. lessened its holdings in Candel Therapeutics, Inc. (NASDAQ:CADL) by 13.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,000 shares of the company’s stock after selling 3,000 shares during the quarter. Vontobel Holding Ltd. owned 0.06% of Candel Therapeutics worth $165,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CADL. FMR LLC bought a new stake in shares of Candel Therapeutics in the third quarter valued at about $46,000. MetLife Investment Management LLC bought a new stake in Candel Therapeutics during the third quarter worth about $87,000. Atom Investors LP bought a new stake in Candel Therapeutics during the third quarter worth about $103,000. Barclays PLC lifted its position in Candel Therapeutics by 327.1% during the third quarter. Barclays PLC now owns 28,688 shares of the company’s stock worth $199,000 after purchasing an additional 21,971 shares during the period. Finally, HB Wealth Management LLC lifted its position in Candel Therapeutics by 54.1% during the fourth quarter. HB Wealth Management LLC now owns 87,300 shares of the company’s stock worth $696,000 after purchasing an additional 30,642 shares during the period. Institutional investors own 13.93% of the company’s stock.

Wall Street Analyst Weigh In

CADL has been the subject of several recent analyst reports. Bank of America initiated coverage on shares of Candel Therapeutics in a research report on Friday, February 7th. They set a “buy” rating and a $15.00 price objective for the company. Canaccord Genuity Group initiated coverage on shares of Candel Therapeutics in a research report on Wednesday. They set a “buy” rating and a $20.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective (up previously from $11.00) on shares of Candel Therapeutics in a research report on Wednesday, December 18th. Finally, Citigroup began coverage on shares of Candel Therapeutics in a research report on Thursday. They set a “buy” rating and a $25.00 price objective for the company.

Candel Therapeutics Trading Down 4.8 %

CADL stock opened at $11.63 on Friday. The stock has a market capitalization of $377.74 million, a P/E ratio of -6.72 and a beta of -1.25. Candel Therapeutics, Inc. has a 12 month low of $1.34 and a 12 month high of $14.60. The firm has a 50-day moving average price of $8.20 and a 200-day moving average price of $6.63.

Insider Activity

In other news, insider William Garrett Nichols sold 13,935 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $4.56, for a total value of $63,543.60. Following the completion of the transaction, the insider now owns 100,547 shares of the company’s stock, valued at $458,494.32. This represents a 12.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Francesca Barone sold 13,673 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $8.22, for a total value of $112,392.06. Following the completion of the transaction, the insider now directly owns 124,207 shares of the company’s stock, valued at $1,020,981.54. This represents a 9.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 75,856 shares of company stock valued at $470,044 over the last quarter. 41.60% of the stock is owned by company insiders.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.